Table 2 Association analysis between clinico-pathological characteristics and ALK-CNG

Gender

128

0.59

 Male

41 (51.9)

28 (35.4)

10 (12.7)

79 (100.0)

 Female

30 (61.2)

14 (28.6)

5 (10.2)

49 (100.0)

Cancer familiarity

110

0.44

 No

18 (54.5)

13 (39.4)

2 (6.1)

33 (100.0)

 Yes

41 (53.2)

25 (32.5)

11 (14.3)

77 (100.0)

Smoking status

120

0.03

 Never

20 (80.0)

4 (16.0)

1 (4.0)

25 (100.0)

 Current

24 (54.5)

13 (29.5)

7 (15.9)

44 (100.0)

 Former

22 (43.1)

23 (45.1)

6 (11.8)

51 (100.0)

Comorbidity

121

0.19

 No

23 (67.6)

8 (23.5)

3 (8.8)

34 (100.0)

 Yes

43 (49.4)

33 (37.9)

11 (12.6)

87 (100.0)

Performance Status sec. ECOG

112

0.63

 0

43 (57.3)

24 (32)

8 (10.7)

75 (100.0)

 1

12 (42.9)

11 (39.3)

5 (17.9)

28 (100.0)

 2–3

6 (66.7)

2 (22.2)

1 (11.1)

9 (100.0)

Histology

128

0.83

 Adenocarcinoma

63 (55.8)

38 (33.6)

12 (10.6)

113 (100.0)

 Squamous

3 (50.0)

2 (33.3)

1 (16.7)

6 (100.0)

 Other

5 (55.6)

2 (22.2)

2 (22.2)

9 (100.0)

T descriptor

115

0.06

 1–2

28 (48.3)

25 (43.1)

5 (8.6)

58 (100.0)

 3–4

36 (63.2)

13 (22.8)

8 (14.0)

57 (100.0)

N descriptor

108

0.52

 0

10 (45.5)

10 (45.5)

2 (9.1)

22 (100.0)

 1–2–3

47 (54.7)

28 (32.6)

11 (12.8)

86 (100.0)

M descriptor

128

0.85

 0

29 (58.0)

16 (32.0)

5 (10.0)

50 (100.0)

 1

42 (53.8)

26 (33.3)

10 (12.8)

78 (100.0)

Disease stage

126

0.14

 I–II

12 (48.0)

12 (48.0)

1 (4.0)

25 (100.0)

 III–IV

57 (56.4)

30 (29.7)

14 (13.9)

101 (100.0)

Grading

54

0.62

 1

5 (55.6)

4 (44.4)

0 (0)

9 (100.0)

 2

4 (33.3)

6 (50.0)

2 (16.7)

12 (100.0)

 3

15 (45.3)

12 (36.4)

6 (18.2)

33 (100.0)

Response rate to 1st line therapy

73

0.92

 No

28 (62.2)

12 (26.7)

5 (11.1)

45 (100.0)

 Yes

17 (60.7)

7 (25.0)

4 (14.3)

28 (100.0)